>>Signaling Pathways>> Tyrosine Kinase>> TAM Receptor>>DS-1205b free base

DS-1205b free base

Catalog No.GC62597

DS-1205b 유리 염기는 1.3 nM의 IC50으로 AXL 키나제의 강력하고 선택적 억제제입니다. DS-1205b 유리 염기는 또한 각각 63, 104 및 407 nM의 IC50으로 MER, MET 및 TRKA를 억제합니다. DS-1205b 유리 염기는 시험관 내 세포 이동 및 생체 내 종양 성장을 억제할 수 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

DS-1205b free base Chemical Structure

Cas No.: 1855860-24-0

Size 가격 재고 수량
5 mg
US$495.00
재고 있음
10 mg
US$855.00
재고 있음
25 mg
US$1,755.00
재고 있음
50 mg
US$2,925.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo[1].

DS-1205b (0.3-33 μM; 2-24 h) inhibits hGAS6-induced migration in NIH3T3-AXL cells (EC50=2.7 nM)[1].DS-1205b (1-10000 μM; 2-24 h) significantly inhibits the phosphorylation of AXL in NIH3T3-AXL cells. DS-1205b decreases NIH3T3 cell proliferation but not obviously inhibits growth (GI50>10,000 nM)[1].

DS-1205b (3.1-50 mg/kg; p.o. bid for 5 d) exhibits pAXL inhibition mediated antitumor effects in mice[1].

[1]. Jimbo T, et, al. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model. Oncotarget. 2019 Aug 27;10(50):5152-5167.

리뷰

Review for DS-1205b free base

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DS-1205b free base

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.